Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
- PMID: 14568012
- DOI: 10.1016/j.abb.2003.08.016
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
Abstract
Long-lived structural proteins, collagen and elastin, undergo continual non-enzymatic crosslinking during aging and in diabetic individuals. This abnormal protein crosslinking is mediated by advanced glycation end products (AGEs) generated by non-enzymatic glycosylation of proteins by glucose. The AGE-derived protein crosslinking of structural proteins contributes to the complications of long-term diabetes such as nephropathy, retinopathy, and neuropathy. AGE-crosslinks have also been implicated in age-related cardiovascular diseases. Potential treatment strategies for these AGE-derived complications include prevention of AGE-formation and breaking of the existing AGE-crosslinks. The therapeutic potential of the AGE-inhibitor, pimagedine (aminoguanidine), has been extensively investigated in animal models and in Phase 3 clinical trials. This review presents the pre-clinical and clinical studies using ALT-711, a highly potent AGE-crosslink breaker that has the ability to reverse already-formed AGE-crosslinks. Oral administration of ALT-711 has resulted in a rapid improvement in the elasticity of stiffened myocardium in experimental animals. Topical administration of ALT-711 was effective in improving the skin hydration of aged rats. The therapeutic potential of crosslink breakers for cardiovascular complications and dermatological alterations associated with aging and diabetes is discussed.
Similar articles
-
Crosslink breakers: a new approach to cardiovascular therapy.Curr Opin Cardiol. 2004 Jul;19(4):336-40. doi: 10.1097/01.hco.0000127135.73849.4f. Curr Opin Cardiol. 2004. PMID: 15218393 Review.
-
Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links.Expert Opin Investig Drugs. 2001 Nov;10(11):1977-87. doi: 10.1517/13543784.10.11.1977. Expert Opin Investig Drugs. 2001. PMID: 11772301 Review.
-
AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats.Arch Biochem Biophys. 2003 Apr 1;412(1):42-6. doi: 10.1016/s0003-9861(03)00015-8. Arch Biochem Biophys. 2003. PMID: 12646266
-
Pimagedine: a novel therapy for diabetic nephropathy.Expert Opin Investig Drugs. 2002 Apr;11(4):565-74. doi: 10.1517/13543784.11.4.565. Expert Opin Investig Drugs. 2002. PMID: 11922864 Review.
-
An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2809-13. doi: 10.1073/pnas.040558497. Proc Natl Acad Sci U S A. 2000. PMID: 10706607 Free PMC article.
Cited by
-
In vivo glycation-interplay between oxidant and carbonyl stress in bone.JBMR Plus. 2024 Aug 8;8(11):ziae110. doi: 10.1093/jbmrpl/ziae110. eCollection 2024 Nov. JBMR Plus. 2024. PMID: 39386996 Review.
-
The mechanics of the retina: Müller glia role on retinal extracellular matrix and modelling.Front Med (Lausanne). 2024 Sep 4;11:1393057. doi: 10.3389/fmed.2024.1393057. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39296899 Free PMC article. Review.
-
Empowering canonical biochemicals with cross-linked novelty: Recursions in applications of protein cross-links.Proteins. 2023 Aug 17:10.1002/prot.26571. doi: 10.1002/prot.26571. Online ahead of print. Proteins. 2023. PMID: 37589191 Free PMC article. Review.
-
Advanced Glycation End Products in Health and Disease.Microorganisms. 2022 Sep 15;10(9):1848. doi: 10.3390/microorganisms10091848. Microorganisms. 2022. PMID: 36144449 Free PMC article. Review.
-
Therapeutic Potential of Phlorotannin-Rich Ecklonia cava Extract on Methylglyoxal-Induced Diabetic Nephropathy in In Vitro Model.Mar Drugs. 2022 May 27;20(6):355. doi: 10.3390/md20060355. Mar Drugs. 2022. PMID: 35736158 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
